BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an ...

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseases Capricor remains on track for the August 31, ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present on EDG-5506, an orally ...

Craig McDonald, M.D., Professor and Chair, Department of Physical Medicine & Rehabilitation, Professor of Pediatrics, Director MDA Neuromuscular Disease Clinics ...

The drug tadalafil (Cialis, Lilly), already approved to treat erectile dysfunction and pulmonary hypertension, also corrects abnormal blood flow in exercised forearms of men with Becker muscular ...

– Trial met primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to date – – On ...

At the 44th Annual J.P. Morgan Healthcare Conference in early January 2026, Edgewise Therapeutics outlined its 2026 clinical ...

SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

– Company to host an Industry Forum to discuss the lived experience of Becker and clinical advancements featuring a leading neuromuscular disease expert and a patient advocate – Edgewise is sponsoring ...